SCHEMBL4674765

SCHEMBL4674765

O=C(Cc1cscc1S(=O)(=O)c1ccccc1)C(=O)c1nc[nH]n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.36
MMP12 P39900 8/20 0.36
MMP13 P45452 8/20 0.36
MMP14 P50281 8/20 0.36
MMP9 P14780 7/20 0.36
MMP8 P22894 6/20 0.36
MMP16 P51512 6/20 0.36
MMP1 P03956 6/20 0.36
MMP3 P08254 6/20 0.36
MAPT P10636 1/20 0.34
ALDH1A1 P00352 2/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2A P28223 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NAMPT P43490 1/20 0.32
ADAM17 P78536 1/20 0.32
KMT2A Q03164 1/20 0.32
CCNE2 O96020 1/20 0.31
CCNE1 P24864 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672013 0.90 MMP1 (0.37) MMP2MMP12MMP13MMP14MMP9
SCHEMBL4676016 0.90 MAPT (0.40) MAPTALDH1A1KDM4ENPSR1NAMPT
SCHEMBL4670967 0.84 MMP2 (0.37) MMP2MMP12MMP13MMP14MMP9
SCHEMBL4676442 0.82 MMP2 (0.36) MMP2MMP12MMP13MMP14MMP9
SCHEMBL4675843 0.82 MMP2 (0.36) MMP2MMP12MMP13MMP14MMP9
SCHEMBL4676445 0.81 SLC6A2 (0.33) SLC6A2
SCHEMBL4676736 0.80 POLB (0.37) MMP2MMP12MMP13MMP14MMP9
SCHEMBL4674716 0.80 HDAC1 (0.33) MMP2MMP12MMP13MMP14MMP9
SCHEMBL4674637 0.80 NPSR1 (0.43) MMP2MMP12MMP13MMP14MMP9
SCHEMBL4677157 0.79 PTGS2 (0.33) MAPTALDH1A1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MMP2 1886/4885MMP12 3456/4885MMP13 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.